ERBB2 and breast carcinoma: Then, based on the results of OlympiAD trial [7], the indication for olaparib was expanded to include patients with germline BRCA mutated and HER2-negative inoperable or recurrent breast cancer who had received prior chemotherapy in July 2018 [11].